| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
Coronary heart disease (Takotsubo s syndrome)BevacizumabKidney (Neoplasm)SunitinibSorafenibTemsirolimusColon and rectum (Neoplasia)CetuximabVEGFPegaptanibRanibizumabPazopanibEverolimusGlioblastoma| 1 | 2008 | Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. | 
| + | - | nl | Ther Clin Risk Manag 4(6):1367-70 (2008) |
| 2 | 2010 | Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. |
| + | - | nl | Health Technol Assess 14(2):1-184, iii-iv (2010) |
| 3 | 2007 | Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. |
| + | - | nl | Health Technol Assess 11(12):1-128, iii-iv (2007) |
| 4 | 2004 | Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. |
| + | - | nl | Angiogenesis 7(4):335-45 (2004) |
| 5 | 2005 | Bevacizumab--current status and future directions. |
| + | - | nl | Ann Oncol 16(7):999-1004 (2005) |
| 6 | 2007 | A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). |
| + | - | nl | Indian J Ophthalmol 55(6):437-9 (2007) |
| 7 | 2007 | Bevacizumab: off-label use in ophthalmology. |
| + | - | nl | Indian J Ophthalmol 55(6):417-20 (2007) |
| 8 | 2010 | Targeted therapy for renal cell cancer: current perspectives. |
| + | - | nl | Discov Med 10(54):394-405 (2010) |
| 9 | 2007 | Vascular endothelial growth factor: biology and therapeutic applications. |
| + | - | nl | Int J Biochem Cell Biol 39(7-8):1349-57 (2007) |
| 10 | 2010 | Bevacizumab. |
| + | - | nl | Oncologist 15(8):819-25 (2010) |
| 11 | 2009 | FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. |
| + | - | nl | Oncologist 14(11):1131-8 (2009) |
